Icometrix has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its icobrain ep solution.
Icobrain ep helps to identify the causes of intractable or uncontrollable epilepsy by providing clinicians with easy-to-interpret quantitative reports. The solution leverages artificial intelligence (AI) to assess the brain MRI scans and devise the report.
With this solution, icometrix seeks to improve detection of the seizure focus in patients with intractable epilepsy expediting diagnosis and subsequent treatment.
Center For Diagnostic Imaging medical director Blake Johnson said: “Artificial intelligence is being employed to improve the efficiency and sensitivity of radiologists, through workflow enhancement, image triage, quantitative analysis and identification of pathological findings.
“Tools like icobrain facilitate the detection of subtle cortical abnormalities in epilepsy patients, which can be easily overlooked with traditional image interrogation.
“This AI-based technology improves our sensitivity and efficiency when evaluating such cases.”
Epilepsy is one of the most common neurological disorders affecting children as well as adults.
Around one in every three epilepsy patients develops intractable epilepsy, primarily due to malformations in the cortex and subtle neuronal loss in the deepest portion of the temporal lobe.
Icometrix CEO Dr Wim Van Hecke said: “The expansion of our icobrain portfolio is the result of continuous efforts to improve patient care by addressing clinical needs for people with neurological diseases.
“Icobrain ep is one of many solutions we will launch in 2020.”
Icometrix is engaged in the development of software solutions to procure data from brain MR and CT scans for various neurological disorders.
The company has offices in Belgium and the US.